RELATIONSHIP BETWEEN UNDERCARBOXYLATED OSTEOCALCIN AND OSTEOPROTEGERIN IN KNEE OSTEOARTHRITIS
Keywords:
Osteoarthritis, Undercarboxylated Osteocalcin, Osteoprotegerin, Bone, CartilageAbstract
Objective: The purpose of the present study was to evaluate the possible association between the serum levels of undercarboxylated osteocalcin (ucOC) and osteoprotegerin (OPG) in patients with knee osteoarthritis (OA).
Methods: Twenty patients (10 men and 10 women) diagnosed to have knee OA, and twenty healthy subjects of matching age, sex, and BMI as a control group, were enrolled in this study. Serum levels of ucOC and OPG, were assayed using the corresponding human ELISA kits.
Results: Patients with knee OA, showed a statistically significant elevation in serum levels of ucOC (P<0.001), and a statistically significant reduction in that of OPG (P<0.0001), as compared to the control group. Also, there is significant negative correlation (r=-0.554, p= 0.0113) between the serum levels of ucOC and OPG in knee OA patients.
Conclusion: there is possible association between the serum levels of ucOC and OPG in patients with knee OA.
Downloads
References
Altman RD. The classification of osteoarthritis. J Rheumatol Suppl 1995;43:42–3.
Lawrence RC, Felson DT, Helmick CG, Arnold LM, Choi H, Deyo RA, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States: Part II. Arthritis Rheum 2008;58(1):26–35.
Wilder FV, Hall BJ, Barrett JP, Lemrow NB. History of acute knee injury and osteoarthritis of the knee: a prospective epidemiological assessment: the clearwater osteoarthritis study. Osteoarthritis Cartilage 2002;10(8):611–6.
Cooper C, Snow S, McAlindon TE, Kellingray S, Stuart B, Coggon D, Dieppe PA. Risk factors for the incidence and progression of radiographic knee osteoarthritis. Arthritis Rheum 2000;43(5):995–1000.
Niu J, Zhang YQ, Torner J, Nevitt M, Lewis CE, Aliabadi P, Sack B, Clancy M, et al. Is obesity a risk factor for progressive radiographic knee osteoarthritis? Arthritis Rheum 2009;61(3):329–35.
Wang Y, Beydoun MA. The obesity epidemic in the United States--gender, age, socioeconomic, racial/ethnic, and geographic characteristics: a systematic review and meta-regression analysis. Epidemiol Rev 2007;29:6–28.
Aigner T. Osteoarthritis. Curr Opin Rheum 2007;19:427-8.
Goldring MB, Goldring SR. Osteoarthritis. J Cell Physiol 2007;213:626-34.
Burr DB, Gallant MA. Bone remodelling in osteoarthritis. Nat Rev Rheumatol 2012;8:665-73.
Pantsulaia I, Kalichman L, Kobyliansky E. Association between radiographic handosteoarthritis and RANKL, OPG and inflammatory markers. Osteoarthritis Cartilage 2010;18:1448-53.
Upton AR, Holding CA, Dharmapatni AA, Haynes DR. The expression of RANKL and OPG in the various grades of osteoarthritic cartilage. Rheumatol Int 2012;32:535-40.
Terpos E, Szydlo R, Apperley JF, Hatjiharissi E, Politou M, Meletis J, et al. Soluble receptor activator of nuclear factor kappa-B ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index. Blood 2003;102:1064–9.
Kim KW, Cho ML, Lee SH, Oh HJ, Kang CM, Ju JH, et al. Human rheumatoid synovial fibroblasts promote osteoclastogenic activity by activating RANKL via TLR-2 and TLR-4 activation. Immunol Lett 2007;110:54–64.
Fonseca JE, Cortez-Dias N, Francisco A, Sobral M, Canhao H, Resende C, et al. Inflammatory cell infiltrate and RANKL/OPG expression in rheumatoid synovium: comparison with other inflammatory arthropathies and correlation with outcome. Clin Exp Rheumatol 2005;23:185–92.
Logar DB, Komadina R, Prezelj J, Ostanek B, Trost Z, Marc J. Expression of bone resorption genes in osteoarthritis and in osteoporosis. J Bone Miner Metab 2007;25:219–25.
Razzaque MS. Osteocalcin: a pivotal mediator or an innocent bystander in energy metabolism? Neph Dial Transpl 2011;26(1):42-5.
Nielsen-Marsh CM, Richards MP, Hauschka PV, Thomas-Oates JE, Trinkaus E, Pettitt PB, et al. Osteocalcin protein sequences of Neanderthals and modern primates. PNAS 2005;102(12):4409-13.
Booth SL, Centi A, Smith SR, Gundberg C. The role of osteocalcin in human glucose metabolism: marker or mediator? Nat Rev Endocrinol 2013;9(1):43-55.
Radin EL, Rose RM. Role of subchondral bone in the initiation and progression of cartilage damage. Clin Orthop Relat Res 1986;213:34–40.
Radin EL, Paul IL, Tolkoff MJ. Subchondral bone changes in patients with early degenerative joint disease. Arthritis Rheum 1970;13:400–5.
Sambrook P, Naganathan V. What is the relationship between osteoarthritis and osteoporosis? Baillieres Clin Rheumatol 1997;11:695–710.
Dequeker J, Aerssens J, Luyten FP. Osteoarthritis and osteoporosis: clinical and research evidence of inverse relationship. Aging Clin Exp Res 2003;15:426–39.
Franklin J, Englund M, Ingvarsson T, Lohmander S. The association between hip fracture and hip osteoarthritis: a case–control study. BMC Musculoskelet Disord England 2010;26:274.
Day JS, Ding M, Van der Linden JC, Hvid I, Sumner DR, Weinans H. A decreased subchondral trabecular bone tissue elastic modulus is associated with prearthritic cartilage damage. J Orthop Res 2001;19:914–8.
Kamibayashi L, Wyss UP, Cooke TD, Zee B. Trabecular microstructure in the medial condyle of the proximal tibia of patients with knee osteoarthritis. Bone 1995;17:27–35.
Kwan Tat S, Amiable N, Pelletier JP, Boileau C, Lajeunesse D, Duval N. Modulation of OPG, RANK and RANKL by human chondrocytes and their implication during osteoarthritis. Rheumatol (Oxford) 2009;48:1482–90.
Kwan Tat S, Pelletier JP, Lajeunesse D, Fahmi H, Lavigne M, Martel-Pelletier J. The differential expression of osteoprotegerin (OPG) and receptor activator of nuclear factor kappaB ligand (RANKL) in human osteoarthritic subchondral bone osteoblasts is an indicator of the metabolic state of these disease cells. Clin Exp Rheumatol 2008;26:295–304.
Moreno-Rubio J, Herrero-Beaumont G, Tardio L, Alvarez-Soria MA, Largo R. Nonsteroidal antiinflammatory drugs and prostaglandin E(2) modulate the synthesis of osteoprotegerin and RANKL in the cartilage of patients with severe knee osteoarthritis. Arthritis Rheum 2010;62:478–88.
Shimizu S, Asou Y, Itoh S, Chung UI, Kawaguchi H, Shinomiya K. Prevention of cartilage destruction with intraarticular osteoclastogenesis inhibitory factor/osteoprotegerin in a murine model of osteoarthritis. Arthritis Rheum 2007;56:3358–65.
Kadri A, Ea H, Bazille C, Hannouche D, Liote´ F, Cohen-Solal M. Osteoprotegerin inhibits cartilage degradation through an effect on trabecular bone in murine experimental osteoarthritis. Arthritis Rheum 2008;58:2379–86.
Shimizu S, Asou Y, Itoh S, Chung UI, Kawaguchi H, Shinomiya K. Prevention of cartilage destruction with intraarticular osteoclastogenesis inhibitory factor/osteoprotegerin in a murine model of osteoarthritis. Arthritis Rheum 2007;56:3358–65.
Vik A, Mathiesen EB, Brox J, Wilsgaard T, Njølstad I, Jørgensen L. Relation between serum osteoprotegerin and carotid intima media thickness in a general population–the Tromsø Study. J Thromb Haemost 2010;8:2133–9.
Benslimane-Ahmim Z, Heymann D, Dizier B, Lokajczyk A, Brion R, Laurendeau I. Osteoprotegerin, a new actor in vasculogenesis, stimulates endothelial colony-forming cells properties. J Thromb Haemost 2011;9(4):834-43.
Poser JW, Price PA. A method for decarboxylation of γ-carboxyglutamic acid in proteins. J Biol Chem 1979;254:431–6.
Engelke JA, Hale JE, Suttie JW, Price PA. Vitamin K-dependent carboxylase: utilization of decarboxylated bone Gla protein and matrix Gla protein as substrates. Biochim Biophys Acta 1991;1078(1):31-4.
Kalkwarf HJ, Khoury JC, Bean J, Elliot JG. Vitamin K, bone turnover, and bone mass in girls. Am J Clin Nutr 2004;80(4):1075-80.
Yamauchi M, Yamaguchi T, Nawata K, Takaoka S, Sugimoto T. Relationships between undercarboxylated osteocalcin and vitamin K intakes, bone turnover, and bone mineral density in healthy women. Clin Nutr 2010;29:761-5.
Naito K, Watari T, Obayashi O, Katsube S, Nagaoka I, Kaneko K. Relationship between serum undercarboxylated osteocalcin and hyaluronan levels in patients with bilateral knee osteoarthritis. Int J Mol Med 2012;29(5):756-60.